Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA.
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Eur Urol. 2015 Oct;68(4):600-8. doi: 10.1016/j.eururo.2014.08.074. Epub 2014 Sep 18.
Few studies have reported on late declines and long-term health-related quality of life (HRQOL) after prostate cancer (PCa) treatment.
We assessed long-term HRQOL following various treatments for localized PCa.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study of HRQOL up to 10 yr after treatment used a prospectively accrued, nationwide PCa registry that collects longitudinal patient-reported HRQOL.
Various primary treatments for localized PCa.
The Medical Outcomes Studies 36-item Short Form and the University of California, Los Angeles, Prostate Cancer Index characterized physical function, mental health, and sexual, urinary, and bowel function and bother. Repeated measures mixed-model analysis assessed change in HRQOL by treatment over time, and logistic regression was used to measure the likelihood of a clinically significant decline in HRQOL.
Among 3294 men, 1139 (34%) underwent nerve-sparing radical prostatectomy (NSRP), 860 (26%) underwent non-NSRP, 684 (21%) underwent brachytherapy, 386 (12%) underwent external beam radiotherapy, 161 (5%) underwent primary androgen deprivation therapy, and 64 (2%) pursued watchful waiting/active surveillance. Median follow-up was 74 mo (interquartile range: 50-102). Most treatments resulted in early declines in HRQOL, with some recovery over the next 1-2 yr and a plateau in scores thereafter. Surgery had the largest impact on sexual function and bother and on urinary function, radiation had the strongest effect on bowel function, and androgen deprivation therapy had the strongest effect on physical function. The main limitation was attrition among the cohort.
Although most men experience initial declines in HRQOL in the first 2 yr after treatment, there is little change from 3 to 10 yr and most differences between treatments attenuated over time.
Various treatments for prostate cancer result in a distinct constellation of adverse effects on health-related quality of life, which may have a long-term impact. These findings are helpful regarding shared decision making over choice of primary treatment.
鲜有研究报道前列腺癌(PCa)治疗后的晚期下降和长期健康相关生活质量(HRQOL)。
我们评估了各种局部 PCa 治疗后的长期 HRQOL。
设计、地点和参与者:这项 HRQOL 队列研究使用前瞻性累积的全国性 PCa 登记处,该登记处收集纵向患者报告的 HRQOL,对治疗后长达 10 年的 HRQOL 进行了研究。
各种用于治疗局限性前列腺癌的主要方法。
采用医疗结局研究 36 项简短形式和加利福尼亚大学洛杉矶分校前列腺癌指数来评估身体功能、心理健康以及性、尿和肠功能和困扰。重复测量混合模型分析评估了随时间推移治疗对 HRQOL 的变化,逻辑回归用于测量 HRQOL 临床显著下降的可能性。
在 3294 名男性中,1139 名(34%)接受了神经保留根治性前列腺切除术(NSRP),860 名(26%)接受了非 NSRP,684 名(21%)接受了近距离放射治疗,386 名(12%)接受了外照射放射治疗,161 名(5%)接受了原发性雄激素剥夺治疗,64 名(2%)选择了观察等待/主动监测。中位随访时间为 74 个月(四分位距:50-102)。大多数治疗方法最初会导致 HRQOL 下降,在接下来的 1-2 年内会有一些恢复,此后评分趋于平稳。手术对性功能和困扰以及尿功能的影响最大,放射治疗对肠功能的影响最强,雄激素剥夺治疗对身体功能的影响最强。主要限制因素是队列中存在流失。
尽管大多数男性在治疗后最初 2 年内会经历 HRQOL 的初始下降,但从 3 年到 10 年几乎没有变化,并且治疗之间的大多数差异随着时间的推移而减弱。
各种治疗前列腺癌的方法会对健康相关生活质量产生明显不同的不良影响,这些影响可能会长期存在。这些发现有助于在选择主要治疗方法时进行共同决策。